Genprex (GNPX) Competitors

$0.87 +0.01 (+0.58%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+0.57%)

As of 05/8/2026 07:25 PM Eastern

GNPX vs. DARE, HOWL, BTAI, PLRZ, and SNTI

Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Dare Bioscience (DARE), Werewolf Therapeutics (HOWL), BioXcel Therapeutics (BTAI), Polyrizon (PLRZ), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry.

How does Genprex compare to Dare Bioscience?

Genprex (NASDAQ:GNPX) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Dare Bioscience had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for Dare Bioscience and 0 mentions for Genprex. Genprex's average media sentiment score of 0.00 equaled Dare Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Genprex	Neutral
Dare Bioscience	Neutral

14.1% of Genprex shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 0.4% of Genprex shares are held by company insiders. Comparatively, 4.8% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genprex has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 263.64%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dare Bioscience's return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-464.05%	-275.54%
Dare Bioscience	N/A	N/A	-56.52%

Dare Bioscience has higher revenue and earnings than Genprex. Dare Bioscience is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A
Dare Bioscience	$1.03M	38.87	-$13.40M	-$1.25	N/A

Summary

Dare Bioscience beats Genprex on 11 of the 13 factors compared between the two stocks.

How does Genprex compare to Werewolf Therapeutics?

Genprex (NASDAQ:GNPX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Werewolf Therapeutics' return on equity of -176.04% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-464.05%	-275.54%
Werewolf Therapeutics	N/A	-176.04%	-69.87%

Genprex has a beta of -0.94, indicating that its share price is 194% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

In the previous week, Werewolf Therapeutics had 15 more articles in the media than Genprex. MarketBeat recorded 15 mentions for Werewolf Therapeutics and 0 mentions for Genprex. Werewolf Therapeutics' average media sentiment score of 0.04 beat Genprex's score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genprex	Neutral
Werewolf Therapeutics	Neutral

14.1% of Genprex shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 0.4% of Genprex shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A
Werewolf Therapeutics	N/A	N/A	-$60.82M	-$1.24	N/A

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 451.47%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Werewolf Therapeutics beats Genprex on 11 of the 13 factors compared between the two stocks.

How does Genprex compare to BioXcel Therapeutics?

Genprex (NASDAQ:GNPX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Genprex has higher earnings, but lower revenue than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A
BioXcel Therapeutics	$640K	51.62	-$69.90M	-$6.71	N/A

Genprex has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 801.64%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, BioXcel Therapeutics' average media sentiment score of 1.00 beat Genprex's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genprex	Neutral
BioXcel Therapeutics	Positive

14.1% of Genprex shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 0.4% of Genprex shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genprex has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -10,887.38%. BioXcel Therapeutics' return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-464.05%	-275.54%
BioXcel Therapeutics	-10,887.38%	N/A	-181.48%

Summary

BioXcel Therapeutics beats Genprex on 11 of the 14 factors compared between the two stocks.

How does Genprex compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A

Polyrizon has a beta of -2.04, meaning that its share price is 304% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500.

Polyrizon's return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Genprex	N/A	-464.05%	-275.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polyrizon had 3 more articles in the media than Genprex. MarketBeat recorded 3 mentions for Polyrizon and 0 mentions for Genprex. Polyrizon's average media sentiment score of 0.23 beat Genprex's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Neutral
Genprex	Neutral

14.1% of Genprex shares are owned by institutional investors. 0.4% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Polyrizon beats Genprex on 5 of the 8 factors compared between the two stocks.

How does Genprex compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Senti Biosciences had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Genprex. Senti Biosciences' average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company	Overall Sentiment
Senti Biosciences	Neutral
Genprex	Neutral

Genprex has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,534.89	-$61.44M	-$3.19	N/A
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A

Senti Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 762.24%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Senti Biosciences is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Senti Biosciences has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 0.4% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Senti Biosciences' return on equity of -301.48% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-301.48%	-90.03%
Genprex	N/A	-464.05%	-275.54%

Summary

Senti Biosciences beats Genprex on 12 of the 14 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.01M	$3.37B	$6.25B	$12.12B
Dividend Yield	N/A	2.25%	2.78%	5.20%
P/E Ratio	-0.03	15.36	20.87	25.39
Price / Sales	N/A	298.52	534.03	75.96
Price / Cash	N/A	124.38	43.29	53.47
Price / Book	0.36	7.32	9.98	6.81
Net Income	-$16.23M	$24.17M	$3.54B	$333.04M
7 Day Performance	-5.43%	2.10%	3.50%	3.17%
1 Month Performance	-33.08%	4.39%	4.17%	7.14%
1 Year Performance	-93.90%	78.56%	41.86%	41.22%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.121 of 5 stars	$0.87 +0.6%	N/A	N/A	$9.01M	N/A	N/A	20	Gap Up
DARE Dare Bioscience	2.0843 of 5 stars	$2.39 +4.9%	$10.00 +318.2%	N/A	$34.51M	$1.03M	N/A	30	News Coverage Upcoming Earnings
HOWL Werewolf Therapeutics	2.5364 of 5 stars	$0.71 -1.2%	$3.75 +427.4%	N/A	$34.36M	$1.88M	N/A	40	News Coverage Earnings Report Analyst Downgrade
BTAI BioXcel Therapeutics	2.4974 of 5 stars	$1.25 +1.2%	$11.00 +783.5%	N/A	$33.74M	$640K	N/A	90	Positive News Upcoming Earnings
PLRZ Polyrizon	0.4209 of 5 stars	$17.02 +7.0%	N/A	N/A	$31.98M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. DARE, HOWL, BTAI, PLRZ, and SNTI

How does Genprex compare to Dare Bioscience?

Summary

How does Genprex compare to Werewolf Therapeutics?

Summary

How does Genprex compare to BioXcel Therapeutics?

Summary

How does Genprex compare to Polyrizon?

Summary

How does Genprex compare to Senti Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. DARE, HOWL, BTAI, PLRZ, and SNTI

How does Genprex compare to Dare Bioscience?

Does the media prefer GNPX or DARE?

Do institutionals & insiders believe in GNPX or DARE?

Which has more risk and volatility, GNPX or DARE?

Do analysts recommend GNPX or DARE?

Is GNPX or DARE more profitable?

Which has stronger earnings and valuation, GNPX or DARE?

Summary

How does Genprex compare to Werewolf Therapeutics?

Is GNPX or HOWL more profitable?

Which has more volatility & risk, GNPX or HOWL?

Does the media refer more to GNPX or HOWL?

Do insiders & institutionals believe in GNPX or HOWL?

Which has better valuation and earnings, GNPX or HOWL?

Do analysts rate GNPX or HOWL?

Summary

How does Genprex compare to BioXcel Therapeutics?

Which has higher earnings and valuation, GNPX or BTAI?

Which has more risk & volatility, GNPX or BTAI?

Do analysts rate GNPX or BTAI?

Does the media favor GNPX or BTAI?

Do insiders and institutionals have more ownership in GNPX or BTAI?

Is GNPX or BTAI more profitable?

Summary

How does Genprex compare to Polyrizon?

Which has higher valuation and earnings, PLRZ or GNPX?

Which has more volatility & risk, PLRZ or GNPX?

Is PLRZ or GNPX more profitable?

Do analysts prefer PLRZ or GNPX?

Does the media refer more to PLRZ or GNPX?

Do insiders and institutionals hold more shares of PLRZ or GNPX?

Summary

How does Genprex compare to Senti Biosciences?

Does the media refer more to SNTI or GNPX?

Which has preferable valuation and earnings, SNTI or GNPX?

Do analysts rate SNTI or GNPX?

Which has more volatility & risk, SNTI or GNPX?

Do institutionals & insiders believe in SNTI or GNPX?

Is SNTI or GNPX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools